Urinary tract infection (UTI) is the infection of the lower or upper urinary tract generally due to escherichia coli although other bacteria and fundi may be causative organisms. Symptoms include pain with urination, frequent urination and feeling the need to urinate despite having an empty bladder. Risk factors that may cause UTI include female anatomy, sexual intercourse, diabetes, obesityetc. World Health Organization (WHO) estimates that approximately 50 % of women suffer from UTI at some point of time in their lives resulting in more than 1 million hospitalizations per year. WHO estimates the annual cost of UTI infections treatment to be greater than $1 billion. It has further been stated that 1% of boys and 3-8% of girls are diagnosed with UTI. .
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2540
The Middle East and African urinary tract infection (UTI) drugs market is growing due to factors such as catheter associated UTI, hospital borne infections (nosocomial infections), child birth, old age, obesity, growing health awareness especially about women health etc. However, there remain market constraints such as drug resistance, unmet clinical needs, increasing incidence of chronic diseases etc. Another prominent restrain is the excellent efficacy of present antibiotics specially the quinolones. However the rise of drug resistance has negated this constraint and had opened doors to new drug development as a good strategy for UTI treatment.
Taking all these factors into consideration, the Middle East and Africa UTI drugs market had reached around $ 992.84 million from $ 769 million in 2015 by growing at the CAGR of 4.35%.
Study Objectives Middle East and Africa UTI Drugs Market:
Key Players of Middle East and Africa UTI Drugs Market:
Some of the key players in this market are: Bayer AG, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Cipla Inc., Dr. Reddy’s Laboratories Ltd. and others.
Middle East and Africa UTI drugs market has been segmented on the basis of drug class which comprises of quinolones, aminoglycosides, β-lactam, azoles and others. On the basis of clinical indications this market is segmented into urethritis, cystitis, and pyelonephritis. On the basis of end users the market is segmented into hospitals and self-administered.
Regional Analysis of Middle East and Africa UTI Drugs Market:
UAE is the largest market of UTI drugs in Middle East and African UTI drugs market closely followed by Egypt. South Africa ranks high in the agendas of many Indian based pharmaceutical firms. The rest of African market is the fastest growing market of UTI drug since there are huge unmet medical needs.
The report about Middle East and Africa UTI Drugs Market by Market Research Future comprises extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value & volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of different markets segments and regions.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/mea-uti-drugs-market-2540